EASTONBIOPHARMACEUTICALS(SH:688513) Xin Lang Cai Jing·2026-01-14 07:15Group 1 - Yuan Dong Bio's stock price fell by 4.07% on January 14, closing at 59.18 CNY per share, with a trading volume of 135 million CNY and a turnover rate of 1.26%, resulting in a total market capitalization of 10.447 billion CNY [1] - The company's stock has experienced a continuous decline over three days, with a cumulative drop of 8.36% during this period [1] - Yuan Dong Bio, established on June 1, 2009, and listed on September 2, 2020, specializes in the research, production, and sales of chemical raw materials and chemical drug formulations, with its main revenue sources being 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Group 2 - Hongde Fund holds a significant position in Yuan Dong Bio, with its Hongde Medical Innovation Mixed Fund A (012481) maintaining 27,000 shares, unchanged from the previous period, accounting for 8.53% of the fund's net value, making it the second-largest holding [2] - The fund has incurred a floating loss of approximately 67,800 CNY today, with a total floating loss of 145,800 CNY during the three-day decline [2] - The Hongde Medical Innovation Mixed Fund A was established on February 22, 2023, with a latest scale of 14.8031 million CNY, achieving a year-to-date return of 14.04% and a one-year return of 60.26% [2]